Skip to main content
SpringerLink
Log in

Eyelid Tumors: The Entire Spectrum

  • Chapter
  • First Online:
Ocular Tumors

  • 421 Accesses

Abstract

Tumors arising from the eyelid can be benign or malignant and are classified according to the tissue of origin. Malignant eyelid tumors can potentially be life threatening. A detailed evaluation is required to differentiate benign from malignant tumors depending on the characteristic clinical features. The standard of care involves surgical excision. Malignant eyelid tumors require complete surgical clearance with histopathologically proven negative margins. This prevents recurrences and reduces morbidity and mortality. Adjuvant therapy is indicated in selected case scenarios. The newer development of targeted therapy in malignant eyelid tumors seems promising.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Campbell RJ, Sobin LH. Tumors of the eyelid. Histological typing of tumors of the eye and its adnexa. World Health Organization international histological classification of tumor. 2nd ed. Berlin: Springer Verlag; 1998. p. 3–9.

    Book  Google Scholar 

  2. Chakradeo K, Narsinghpura K, Ekladious A. Sign of Leser-Trélat. BMJ Case Rep. 2016;8:2016.

    Google Scholar 

  3. Boniuk M, Zimmerman LE. Eyelid tumors with reference to lesions confused with squamous cell carcinoma. II. Inverted follicular keratosis. Arch Ophthalmol. 1963;69:698–707.

    Article  CAS  PubMed  Google Scholar 

  4. Lever WF. Inverted follicular keratosis is an irritated seborrheic keratosis. Am J Dermatopathol. 1983;5(5):474.

    Article  CAS  PubMed  Google Scholar 

  5. Person JR. An actinic keratosis is neither malignant nor premalignant: it is an initiated tumor. J Am Acad Dermatol. 2003;48:637–8.

    Article  PubMed  Google Scholar 

  6. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–7.

    Article  CAS  PubMed  Google Scholar 

  7. Chen PR, Kohn SR, Davis DA, Kurzrock R. Muir torre syndrome. Dermatol Clin. 1995;13(1):79–89.

    Article  Google Scholar 

  8. Kersting DW, Helwig EB. Eccrine spiradenoma. AMA Arch Dermatol. 1956;73:199–227.

    Article  CAS  Google Scholar 

  9. Alkatan HM. Nodular hidradenoma of the lower eyelid. Can J Ophthalmol. 2007;42:149–50.

    Article  PubMed  Google Scholar 

  10. Volmar KE, Cummings TJ, Wang WH, Creager AJ, Tyler DS, Xie HB. Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med. 2005;129(5):e113–6.

    PubMed  Google Scholar 

  11. LeBoit PE, Burg G, Weedon D, Sarasain A, editors. World Health Organization classification of tumours. Pathology and genetics of skin tumours. Lyon: IARC Press; 2006. p. 145–6.

    Google Scholar 

  12. Ansai SI, Anan T, Fukumoto T, Saeki H. Tubulopapillary cystic adenoma with apocrine differentiation: a unifying concept for syringocystadenoma papilliferum, apocrine gland cyst, and tubular papillary adenoma. Am J Dermatopathol. 2017;39(11):829–37.

    Article  PubMed  Google Scholar 

  13. Verplancke P, Driessen L, Wynants P, Naeyaert JM. The Schöpf-Schulz-Passarge syndrome. Dermatology. 1998;196(4):463–6.

    Article  CAS  PubMed  Google Scholar 

  14. Helwig EB, Hackney VC. Syringadenoma papilliferum; lesions with and without naevus sebaceous and basal cell carcinoma. AMA Arch Derm. 1955;71:361–72.

    Article  CAS  PubMed  Google Scholar 

  15. Rathi M, Awasthi S, Budania SK, Ahmad F, Dutta S, Kumar A. Brooke-Spiegler syndrome: a rare entity. Case Rep Pathol. 2014;2014:231895.

    PubMed  PubMed Central  Google Scholar 

  16. Bardenstein DS, McLean IW, Nerney J, Boatwright RS. Cowden’s disease. Ophthalmology. 1988;95(8):1038–41.

    Article  CAS  PubMed  Google Scholar 

  17. Boniuk M, Zimmerman LE. Pilomatrixoma (benign calcifying epithelioma) of the eyelids and eyebrow. Arch Ophthalmol. 1963;70:399–406. https://www.ncbi.nlm.nih.gov/pubmed/?term=Boniuk+zimmerman+pilomatrixoma.

    Article  CAS  PubMed  Google Scholar 

  18. Peutz JLA. On a very remarkable case of familial polyposis of the mucous membrane of the intestinal tract and nasopharynx accompanied by peculiar pigmentations of the skin and mucous membrane. Ned Tijdschr Geneeskd. 1921;10:839–47.

    Google Scholar 

  19. Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med. 1949;241:1031–6.

    Article  CAS  PubMed  Google Scholar 

  20. Kopf AW, Bart RS, Hennessey P. Congenital nevocytic nevi and malignant melanomas. J Am Acad Dermatol. 1979;1(2):123–30.

    Article  CAS  PubMed  Google Scholar 

  21. Lorentzen M, Pers M, Bretteville-Jensen G. The incidence of malignant transformation in giant pigmented nevi. Scand J Plast Reconstr Surg. 1977;11:163–7.

    Article  CAS  PubMed  Google Scholar 

  22. Kirzhner M, Jakobiec FA, Kim N. Focal blue nevus of the eyelid margin (mucocutaneous junction): a report of a unique case with a review of the literature. Ophthal Plast Reconstr Surg. 2011;27(5):338–42.

    Article  PubMed  Google Scholar 

  23. Rhodes AR, Silverman RA, Harrist TJ, Perez-Atayde AR. Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: the “LAMB” syndrome. J Am Acad Dermatol. 1984;10(1):72–82.

    Article  CAS  PubMed  Google Scholar 

  24. Singh AD, De Potter P, Fijal BA, Shields CL, Shields JA, Elston RC. Lifetime prevalence of uveal melanoma in white patients with oculo (dermal) melanocytosis. Ophthalmology. 1998;105(1):195–8.

    Article  CAS  PubMed  Google Scholar 

  25. Dasgupta R, Fishman SJ. ISSVA classification. Semin Pediatr Surg. 2014;23(4):158–61.

    Article  PubMed  Google Scholar 

  26. Jackson R. The natural history of strawberry naevi. J Cutan Med Surg. 1998;2:187–9.

    Article  CAS  PubMed  Google Scholar 

  27. Shields CL, Shields JA, Minzter R, Singh AD. Cutaneous capillary hemangiomas of the eyelid, scalp, and digits in premature triplets. Am J Ophthalmol. 2000;129(4):528–31.

    Article  CAS  PubMed  Google Scholar 

  28. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.

    Article  PubMed  Google Scholar 

  29. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–4.

    Article  PubMed  Google Scholar 

  30. Sullivan TJ, Clarke MP, Morin JD. The ocular manifestations of the Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus. 1992;29(6):349–56.

    CAS  PubMed  Google Scholar 

  31. Cannon P, Ajit R, Leatherbarrow B. Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. Clin Exp Dermatol. 2010;35(8):845–8.

    Article  CAS  PubMed  Google Scholar 

  32. Ribera M, Pinto X, Argimon JM, Fiol C, Pujol R, Ferrándiz C. Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med. 1995;99(5):485–90.

    Article  CAS  PubMed  Google Scholar 

  33. Kavoussi H, Ebrahimi A, Rezaei M, Ramezani M, Najafi B, Kavoussi R. Serum lipid profile and clinical characteristics of patients with xanthelasma palpebrarum. An Bras Dermatol. 2016;91(4):468–71.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bhari N, Chiramel MJ, Vedi KK, et al. Necrobiotic xanthogranuloma with multiple myeloma. Clin Exp Dermatol. 2015;40:811–4.

    Article  CAS  PubMed  Google Scholar 

  35. Matsura F, et al. Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypercholesterolemia: a possible pathogenesis of necrobiotic xanthogranuloma. Atherosclerosis. 1999;142:355.

    Article  Google Scholar 

  36. Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8:137.

    Article  PubMed  PubMed Central  Google Scholar 

  37. National Institutes of Health consensus development conference statement: neurofibromatosis. Arch Neurol Chicago. 1988;45:575–8.

    Google Scholar 

  38. Abdi U, Tyagi N, Maheshwari V, Gogi R, Tyagi SP. Tumours of eyelid: a clinicopathologic study. J Indian Med Assoc. 1996;94:405–9, 416, 418.

    CAS  PubMed  Google Scholar 

  39. Abe M, Ohnishi Y, Hara Y, Shinoda Y, Jingu K. Malignant tumor of the eyelid—clinical survey during 22-year period. Jpn J Ophthalmol. 1983;27:175–84.

    CAS  PubMed  Google Scholar 

  40. Sihota RK, Tandon SM, Betharia SM, Arora R. Malignant eyelid tumors in an Indian population. Arch Ophthalmol. 1996;114:108–9.

    Article  CAS  PubMed  Google Scholar 

  41. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111:2151–7.

    Article  PubMed  Google Scholar 

  42. Wang JK, Liao SL, Jou JR, Lai PC, Kao SC, Hou PK, et al. Malignant eyelid tumours in Taiwan. Eye (Lond). 2003;17:216–20.

    Article  Google Scholar 

  43. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103–22.

    Article  PubMed  Google Scholar 

  44. Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol. 1989;33(6):477–90.

    Article  CAS  PubMed  Google Scholar 

  45. Leibovitch I, Huilgol SC, James CL, Hsuan JD, Davis G, Selva D. Periocular keratoacanthoma: can we always rely on the clinical diagnosis? Br J Ophthalmol. 2005;89:1201–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ponti G, Ponz de leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6:980–7.

    Article  PubMed  Google Scholar 

  47. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705–27.

    PubMed  Google Scholar 

  49. Boynton JR, Markowitch W Jr. Mucinous eccrine carcinoma of the eyelid. Arch Ophthalmol. 1998;116(8):1130–1.

    Article  CAS  PubMed  Google Scholar 

  50. Zembowicz A, Garcia CF, Tannous ZS, Mihm MC, Koerner F, Pilch BZ, et al. Endocrine mucin-producing sweat gland carcinoma: twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas. Am J Surg Pathol. 2005;29:1330–9.

    Article  PubMed  Google Scholar 

  51. Shon W, Salomão DR. WT1 expression in endocrine mucin-producing sweat gland carcinoma: a study of 13 cases. Int J Dermatol. 2014;53:1228–34.

    Article  CAS  PubMed  Google Scholar 

  52. Dhaliwal CA, Torgersen A, Ross JJ, Ironside JW, Biswas A. Endocrine mucin-producing sweat gland carcinoma: report of two cases of an under-recognized malignant neoplasm and review of the literature. Am J Dermatopathol. 2013;35:117–24.

    Article  PubMed  Google Scholar 

  53. Hamman MS, Brian Jiang SI. Management of trichilemmal carcinoma: an update and comprehensive review of the literature. Dermatol Surg. 2014;40(7):711–7.

    CAS  PubMed  Google Scholar 

  54. Weiner JM, Hidayat AA. Juvenile fibrosarcoma of the orbit and eyelid. A study of five cases. Arch Ophthalmol. 1983;101(2):253–9.

    Article  CAS  PubMed  Google Scholar 

  55. Shields CL, Shields JA, Honavar SG, Demirci H. Primary ophthalmic rhabdomyosarcoma in 33 patients. Trans Am Ophthalmol Soc. 2001;99:133–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Zitelli JA, Mohs FE, Larson P, Snow S. Mohs micrographic surgery for melanoma. Dermatol Clin. 1989;7(4):833–43.

    Article  CAS  PubMed  Google Scholar 

  57. Cook BE Jr, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98; quiz 2099-100, 2121.

    Article  PubMed  Google Scholar 

  58. Nerad JA. The requisites in ophthalmology oculoplastics surgery: eyelid reconstruction. In: Krachmer JH, editor. Requisites in ophthalmology: oculoplastic surgery. St Louis: Mosby; 2001.

    Google Scholar 

  59. Nijhawan N, Ross MI, Diba R, Ahmadi MA, Esmaeli B. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg. 2004;20(4):291–5.

    Article  PubMed  Google Scholar 

  60. Wilson MW, Fleming JC, Fleming RM, Haik BG. Sentinel node biopsy for orbital and ocular adnexal tumors. Ophthal Plast Reconstr Surg. 2001;17(5):338–44; discussion 344–5.

    Article  CAS  PubMed  Google Scholar 

  61. Amato M, et al. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthal Plast Reconstr Surg. 2003;19(2):102–6.

    Article  PubMed  Google Scholar 

  62. Pfeiffer ML, Savar A, Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade? Ophthal Plast Reconstr Surg. 2013;29(1):57–62.

    Article  PubMed  Google Scholar 

  63. Athar M, Li C, Kim AL, Spiegelman VS, Bickers DR. Sonic hedgehog signaling in basal cell nevus syndrome. Cancer Res. 2014;74(18):4967–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28.

    Article  CAS  PubMed  Google Scholar 

  66. Ozgur OK, Yin V, Chou E, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220–7.

    Article  CAS  PubMed  Google Scholar 

  67. Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841–6.

    Article  CAS  PubMed  Google Scholar 

  68. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011;207:337–42.

    Article  CAS  PubMed  Google Scholar 

  69. Ch’ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008;39:344–9.

    Article  PubMed  CAS  Google Scholar 

  70. Shimizu T, Izumi H, Oga A, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology. 2001;202:203–6.

    Article  CAS  PubMed  Google Scholar 

  71. Engelhardt C, Curiel-Lewandrowski C, Warneke J, Cranmer L. Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy. J Am Acad Dermatol. 2011;65:237–8.

    Article  PubMed  Google Scholar 

  72. Read WL. Squamous carcinoma of the skin responding to erlotinib: three cases. J Clin Oncol. 2007;25:16519.

    Article  Google Scholar 

  73. El-Sawy T, Sabichi AL, Myers JN, et al. Epidermal Growth Factor Receptor Inhibitors for Treatment of Orbital Squamous Cell Carcinoma. Arch Ophthalmol. 2012;130(12):1608–1611.

    Google Scholar 

  74. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33.

    Article  CAS  PubMed  Google Scholar 

  75. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Financial Disclosure

Nil.

Author information

Authors and Affiliations

  1. Ocular Oncology, Orbit and Oculoplasty Services, HORUS Specialty Eye Care, Bangalore, Karnataka, India

    Fairooz P. Manjandavida & Shaifali Chahar

Authors
  1. Fairooz P. Manjandavida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaifali Chahar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Former Professor and Head, Department of Ophthalmology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

    H. V. Nema

  2. Professor, Department of Ophthalmology, Sri Aurobindo Medical College & PG Institute, Indore, India

    Nitin Nema

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Manjandavida, F.P., Chahar, S. (2021). Eyelid Tumors: The Entire Spectrum. In: Nema, H.V., Nema, N. (eds) Ocular Tumors. Springer, Singapore. https://doi.org/10.1007/978-981-15-8384-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-8384-1_14

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-8383-4

  • Online ISBN: 978-981-15-8384-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation